C07K 16/4291
Against ige
Official title: {against IgE}
C07K16/4291 (Against ige) appears on 298 US grants and 536 published applications in this corpus.
Search patents in C07K- Granted patents
- 298
- Published applications
- 536
- Assignees
- 168
- Inventors
- 739
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 4 | 0 |
| 1994 | 2 | 0 |
| 1995 | 5 | 0 |
| 1996 | 6 | 0 |
| 1997 | 7 | 0 |
| 1998 | 1 | 0 |
| 1999 | 7 | 0 |
| 2000 | 3 | 0 |
| 2001 | 7 | 3 |
| 2002 | 0 | 7 |
| 2003 | 6 | 20 |
| 2004 | 10 | 23 |
| 2005 | 5 | 19 |
| 2006 | 6 | 18 |
| 2007 | 10 | 24 |
| 2008 | 11 | 15 |
| 2009 | 5 | 21 |
| 2010 | 14 | 26 |
| 2011 | 7 | 25 |
| 2012 | 12 | 21 |
| 2013 | 13 | 17 |
| 2014 | 13 | 23 |
| 2015 | 15 | 30 |
| 2016 | 9 | 22 |
| 2017 | 18 | 17 |
| 2018 | 9 | 18 |
| 2019 | 12 | 15 |
| 2020 | 6 | 26 |
| 2021 | 7 | 25 |
| 2022 | 17 | 28 |
| 2023 | 11 | 25 |
| 2024 | 15 | 22 |
| 2025 | 14 | 27 |
| 2026 | 9 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Luciferase linked immunosorbent assay6 Oct 2026US 12,753,245 B2Institut Pasteur
- Immunoglobulin variable domains1 Sep 2026US 12,723,072 B2Ablynx N. V.
- Process for improving Omalizumab expression in CHO cells4 Aug 2026US 12,698,345 B2Kashiv Biosciences, LLC
- Displacers of IgE-FceRI28 Jul 2026US 12,692,325 B2Aarhus Universitet
- Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly5 May 2026US 12,617,847 B2Chugai Seiyaku Kabushiki Kaisha
- Thin Wall Cannula8 Oct 2026US 2026/0306753 A1Becton, Dickinson and Company
- Treatment of food allergy using anti-ige antibodies8 Oct 2026US 2026/0308280 A1Novartis AG
- Process of affinity chromatography1 Oct 2026US 2026/0295463 A1Kashiv Biosciences, LLC
- Process of purification of protein3 Sep 2026US 2026/0258078 A1Kashiv Biosciences, LLC
- Improved process of purification of protein20 Aug 2026US 2026/0242412 A1Kashiv Biosciences, LLC
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Polypeptide variants with altered effector function1,378US 6,737,056 B1Genentech, Inc. · 2004
- Transgenic non-human animals for producing heterologous antibodies679US 5,814,318 AGenPharm International, Inc. · 1998